Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | LY2510924 |
Trade Name | |
Synonyms | LY-2510924|LY 2510924 |
Drug Descriptions |
LY2510924 is a selective CXCR4 antagonist that prevents SDF-1 binding, potentially resulting in decreased tumor cell migration (PMID: 25504752, PMID: 32219196). |
DrugClasses | CXCR4 Inhibitor 15 |
CAS Registry Number | 1088715-84-7 |
NCIT ID | C106253 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cytarabine + Idarubicin + LY2510924 | Cytarabine Idarubicin LY2510924 | 0 | 1 |
Durvalumab + LY2510924 | Durvalumab LY2510924 | 0 | 1 |
LY2510924 | LY2510924 | 0 | 0 |
LY2510924 + Sunitinib | LY2510924 Sunitinib | 0 | 0 |